The EHMT1 Knockout HCT 116 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the EHMT1 gene has been disrupted. This loss-of-function model enables investigation of EHMT1-dependent epigenetic regulation in a human colorectal carcinoma background. The polyclonal format preserves genetic diversity while eliminating EHMT1 expression, supporting population-level studies of EHMT1-mediated gene silencing and chromatin dynamics.
The HCT 116 host cell line is a well-characterized human colorectal carcinoma epithelial model harboring a KRAS G13D mutation and exhibiting microsatellite instability (MSI). These genetic features make HCT 116 particularly relevant for studying oncogenic signaling and epigenetic dysregulation. The cell line??s epithelial origin and robust growth characteristics render it suitable for in vitro assays addressing colorectal cancer biology.
EHMT1 encodes a histone methyltransferase that catalyzes mono- and dimethylation of lysine 9 on histone H3 (H3K9me1/me2), a mark associated with transcriptional repression. EHMT1 functions within a complex containing EHMT2/G9a, WIZ, and co-repressors such as CTBP and HDACs. This complex promotes heterochromatin formation and gene silencing by recruiting HP1 proteins. EHMT1 activity is regulated by upstream pathways including PI3K/AKT and Wnt/??-catenin signaling, and it transcriptionally represses tumor suppressor genes as well as autophagy-related genes like LC3 and p62. Through these interactions, EHMT1 integrates external cues with chromatin structure and gene expression programs.
In HCT 116 cells, EHMT1 knockout is predicted to reduce H3K9me2 levels, leading to derepression of tumor suppressors and altered Wnt/??-catenin target gene expression. Given the constitutive KRAS G13D signaling in this line, loss of EHMT1 may modify oncogenic phenotypes such as proliferation, migration, and drug sensitivity. Moreover, EHMT1??s role in autophagy regulation suggests that the knockout model can be used to examine crosstalk between epigenetic silencing and autophagic flux in colorectal cancer.
This knockout cell population is suitable for a range of applications, including cancer epigenetics, histone modification studies, and drug target validation. Researchers can analyze global H3K9me2 levels by western blotting, assess transcriptional changes via RNA-seq or RT-qPCR of downstream targets, and perform ChIP-qPCR to map chromatin modifications. Functional assays such as cell proliferation, migration/invasion, autophagy flux measurements, and drug sensitivity profiling are also compatible. For additional information or custom inquiries, please contact Ascent Research.
